⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2036849 | 0.92 | PAOX (0.67) | — | |
| SCHEMBL12248451 | 0.90 | PAOX (0.70) | — | |
| SCHEMBL25907273 | 0.90 | PAOX (0.70) | — | |
| SCHEMBL18154617 | 0.90 | PAOX (0.70) | — | |
| SCHEMBL280327 | 0.90 | PAOX (0.70) | — | |
| SCHEMBL519505 | 0.82 | — | — | |
| Bromide SCHEMBL11714940 | 0.80 | — | — | |
| SCHEMBL18762845 | 0.80 | ALDH1A1 (0.47) | — | |
| Hydrochloric Acid SCHEMBL167380 | 0.80 | — | — | |
| SCHEMBL24651341 | 0.79 | CES1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137516-A1 | FLUORINATED MONOMERS, ANION EXCHANGE POLYMERS AND METHODS OF MAKING THE SAME | THE CHEMOURS COMPANY FC, LLC (US) | 2025-06-26 | — | — | WO | claimed |
| CN-112266356-A | Asymmetric synthesis method of (S) -chloroquine phosphate | 陈旭桓 | 2021-01-26 | — | — | CN | claimed |
| WO-2025137516-A1 | FLUORINATED MONOMERS, ANION EXCHANGE POLYMERS AND METHODS OF MAKING THE SAME | THE CHEMOURS COMPANY FC, LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-1656983-B1 | Process for deacidification of a gas with an absorbing solution and fractional regeneration | IFP ENERGIES NOW (FR) | 2024-01-24 | — | — | EP | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230123534-A1 | LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF ACTIVE AGENTS | ACUITAS THERAPEUTICS INC (CA) | 2023-04-20 | — | — | US | disclosed |
| CN-114401947-A | Radiolabeled compounds targeting prostate specific membrane antigen | 省卫生服务机构 | 2022-04-26 | — | — | CN | disclosed |
| CN-114364690-A | Novel radiolabeled CXCR4 targeting compounds for diagnosis and therapy | 省卫生服务机构 | 2022-04-15 | — | — | CN | disclosed |
| WO-2021062246-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| CN-112266356-A | Asymmetric synthesis method of (S) -chloroquine phosphate | 陈旭桓 | 2021-01-26 | — | — | CN | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-5977348-A | ESTERIFYING OR ETHERIFYING POLYSACCHARIDE BY MIXING WITH REAGENT UNDER DENSIFIED FLUID UP TO 15% WATER BY VOLUME FOR PERIOD OF TIME; FOR HIGH DEGREE OF SUBSTITUTION WITHOUT USE OF TRADITIONAL ORGANIC SOLVENTS OR REPEATED REACTIONS | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5962473-A | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F | ELI LILLY AND COMPANY (US) | 1999-10-05 | — | — | US | disclosed |
| US-5942536-A | USEFUL FOR TREATING MIGRAINE | ELI LILLY AND COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| EP-0893451-A2 | Polysaccharide modification in densified fluid | National Starch and Chemical Investment Holding Corporation (US) | 1999-01-27 | — | — | EP | disclosed |
| US-5792763-A | MIGRAINES; ANALGESICS; DISEASES LINKED TO DECREASED NEUROTRANMISSION OF SEROTONIN IN MAMMALS | ELI LILLY AND COMPANY (US) | 1998-08-11 | — | — | US | disclosed |
| EP-0835869-A2 | New serotonin 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0824917-A2 | Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis | ELI LILLY AND COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1997013512-A1 | N-[2-SUBSTITUTED-3-(2-AMINOETHYL)-1H-INDOL-5-YL]-AMIDES: NEW 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1997-04-17 | — | — | WO | disclosed |
| EP-0768301-A1 | N-(2-substituted-3-(2-aminoethyl)-1H-indol-5-yl)-amides as new 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |